Biotech Spinoffs Could Come From Pharma’s Acquisition-Based R&D Model
This article was originally published in The Pink Sheet Daily
“Big pharma” will likely continue to rely on licensing or acquiring novel technologies from biotech innovator firms, panelists said at the BayBio 2006 Conference.
You may also be interested in...
HAMBURG, Germany - Due to the increasingly global nature of biotechnology, the Biotechnology Industry Organization's board of directors will meet next month to discuss a proposal to expand its global reach and potentially create a department of international relations, BIO President Jim Greenwood said Nov. 13
Merger will create the leading generic injectable pharmaceutical company in the world.
Takeda sleep aid’s new Rx share has grown more than 50% since campaign began.